CHAIRMAN MOSELEY:
MR. KREY:
The next presentation is a rebuttal by EML.
At the request of the DAAG and the ORERP, EML has agreed to
assist and participate in the quality assurance plan for Phase II.
|
_As Frosty indicated, DRI is indeed responsible for the conduct of the
quality assurance plan, but we have been, and we will continue to be active
iithe-design and logistics of that plan.
The first viewgraph,
subtasks
if you will
in thé-exper imental
selection,
the“in situ.
(A).
This identifies the various
approach to Phase II.
gamma
spectrometry,
soil
These are the site
sampling
and
sample
10
preparation, cestune137 analysis, and plutonium 239-240 analysis.
I have
il
left off in that viewgraph one other task which will be coming down the
12
road much later.
13
and 240 nuclides.
14
the time comes, but it wil] bepart of this subtask.
That is
;the mass isotopic analysis of the plutonium 239
That’sfar _down the road, and we'll address that when
EML has been involved in “Bach of these tasks in one of three ways:
15
16
instruction, reference samples, and dupication.
17
has provided written instructions toeach: of the appropriate ORERP groups
18
for
19
concerned.
20
test its analytical) methods prior to proceeding with the actual Phase II
21
samples,
22
analyzed under previous EML programs.
23
ence samples and blank samples to DRI who will then—insert them blind into
24
the normal sample flow to the analytical contractor>—As faras duplication
each of
these
subtasks,
as
far
In reference samples:
we
have
provided
them
as the
As part of this plan, EML
EML
standard methods
are
at the présent time to allow REECo to
with
typical
samples
which
have
been
In the future we will provide refer-
25 is concerned, EML has intercalibrated its in situ gamma spectrometry system
26
with the system from Livermore at a number of sites.
27
collected or retrieved soil samples from 13 sites where REECo had sampled
28
earlier.
These
particular
samples
179
will
be
InOctober, we have
processed
and
analyzed
at